Diferencia entre revisiones de «Ceftolozane/tazobactam»
Sin resumen de edición |
Sin resumen de edición |
||
| Línea 1: | Línea 1: | ||
==General== | ==General== | ||
*Type: Antibiotic (cephalosporin/beta-lactamase inhibitor combination) | *Type: [[Antibiotic]] (cephalosporin/beta-lactamase inhibitor combination) | ||
*Dosage Forms: IV | *Dosage Forms: IV | ||
*Common Trade Names: Zerbaxa | *Common Trade Names: Zerbaxa | ||
| Línea 8: | Línea 8: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''Safety/efficacy not established in children'' | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: Infant risk cannot be ruled out | ||
*Renal Dosing | *Renal Dosing: 750mg IV q8hr for moderate renal impairment, 375mg IV q8hr for severe impairment | ||
*Hepatic Dosing: no adjustment | |||
*Hepatic Dosing | |||
==Contraindications== | ==Contraindications== | ||
| Línea 25: | Línea 21: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*C. difficile diarrhea | |||
*Renal impairment | |||
*Hypersensitivity | |||
===Common=== | ===Common=== | ||
*Nausea, diarrhea | |||
*Headache | |||
*Fever | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: Ceftolozane- ~3h, Tazobactam- ~1h | ||
*Metabolism: N/A | *Metabolism: N/A | ||
*Excretion: Renal (100%) | *Excretion: Renal (100%) | ||
==Mechanism of Action== | |||
*Ceftolozane: cephalosporin- binds to bacterial PCN-binding proteins, thus inhibiting bacterial cell wall synthesis | |||
*Tazobactam: irreversibly inhibits some penicillinases and cephalosporinases and binds to some chromosomal and plasmid-mediated bacterial beta-lactamases | |||
[[Category:ID]] | [[Category:ID]] | ||
Revisión actual - 18:17 12 jul 2017
General
- Type: Antibiotic (cephalosporin/beta-lactamase inhibitor combination)
- Dosage Forms: IV
- Common Trade Names: Zerbaxa
Adult Dosing
- 1.5 grams (1gm ceftolozane/0.5gm tazobactam) IV q8H
Pediatric Dosing
Safety/efficacy not established in children
Special Populations
- Pregnancy Rating: B
- Lactation: Infant risk cannot be ruled out
- Renal Dosing: 750mg IV q8hr for moderate renal impairment, 375mg IV q8hr for severe impairment
- Hepatic Dosing: no adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- C. difficile diarrhea
- Renal impairment
- Hypersensitivity
Common
- Nausea, diarrhea
- Headache
- Fever
Pharmacology
- Half-life: Ceftolozane- ~3h, Tazobactam- ~1h
- Metabolism: N/A
- Excretion: Renal (100%)
Mechanism of Action
- Ceftolozane: cephalosporin- binds to bacterial PCN-binding proteins, thus inhibiting bacterial cell wall synthesis
- Tazobactam: irreversibly inhibits some penicillinases and cephalosporinases and binds to some chromosomal and plasmid-mediated bacterial beta-lactamases